Clinical Trial Update: LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for LM-108 in combination with toripalimab versus paclitaxel for CCR8-positive gastric and gastroesophageal junction adenocarcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• LM-108
• Toripalimab (Toripalimab)

Snippet

Sponsor: LaNova Medicines Limited | Conditions: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING